Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mixed Incontinence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Mixed Incontinence. Displaying page 1 of 1.
    EudraCT Number: 2008-000968-16 Sponsor Protocol Number: F1J-FR-HAAB Start Date*: 2008-11-18
    Sponsor Name:CeRePP
    Full Title: EFFICACY OF DULOXETINE IN THE TREATMENT OF URINARY INCONTINENCEAFTER PROSTATECTOMIE DUE TO CANCER
    Medical condition: We want to evaluate the effect of Duloxetine 40mg BID (80mg daily dose) on the number of urinary incontinence episodes as shown on a 74 days bladder diary, compared to placebo for male which had a...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046543 Urinary incontinence LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005350-21 Sponsor Protocol Number: A0221064 Start Date*: 2009-02-03
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY OF THE EFFICACY OF FESOTERODINE IN INCREASING URETHRAL PRESSURE IN STRESS URINARY INCONTINENCE PATIENTS
    Medical condition: Stress urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066218 Stress urinary incontinence LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001559-12 Sponsor Protocol Number: A6061024 Start Date*: 2005-08-01
    Sponsor Name:Pfizer
    Full Title: Measurement of Urethral Function in Women with Stress Urinary Incontinence - Evaluation of the Sensitivity of Urethral Reflectometry compared to Urethral Pressure Profilometry, using [S,S]-Reboxeti...
    Medical condition: Stress Urinary Incontinence (SUI)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10042213 VTc
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001021-28 Sponsor Protocol Number: 1208.22 Start Date*: 2005-09-05
    Sponsor Name:Boehringer Ingelheim GmbH
    Full Title: .A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 1...
    Medical condition: stress urinary incontinence and stress predominant mixed urinary incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004307-30 Sponsor Protocol Number: IXA-CSP-001 Start Date*: 2017-03-30
    Sponsor Name:IXALTIS
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BI...
    Medical condition: Mixed Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005401-41 Sponsor Protocol Number: 905-EC-012 Start Date*: 2013-07-03
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warr...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) GB (Completed) SE (Completed) IE (Completed) BE (Completed) PT (Completed) NO (Completed) AT (Completed) FI (Completed) GR (Completed) HU (Completed) ES (Completed) SI (Completed) NL (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024331-16 Sponsor Protocol Number: HULPURO-2010-01 Start Date*: 2012-06-18
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz
    Full Title: Clinical trial phase II to determine the feasibility and safety of using autologous mesenchymal stem cells derived from autologous expanded adipose tissue (ASC) in the local treatment of female uri...
    Medical condition: Urinary incontinence in women due to strain.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003321-14 Sponsor Protocol Number: TS002 Start Date*: 2019-11-01
    Sponsor Name:Tesla Medical s.r.o.
    Full Title: 12-weeks, Open-label, Randomized, Multicenter, Post Marketing Clinical Follow-up Study to Evaluate Safety, Tolerability and Efficacy of the Home-Based electrical Transcutaneous NeuroModulation (eT...
    Medical condition: Naive Subjects With Overactive Bladder (OAB)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004211-31 Sponsor Protocol Number: CCR3894 Start Date*: 2014-08-20
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer
    Medical condition: Adverse effects of radiotherapy for pelvic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001600-38 Sponsor Protocol Number: 27018966IBS3001 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001601-24 Sponsor Protocol Number: 27018966IBS3002 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000245-33 Sponsor Protocol Number: VN21 Start Date*: 2022-05-31
    Sponsor Name:Medical University of Lublin
    Full Title: To evaluate the effect of low-dose naltrexone (LDN) on pain perception and quality of life in women
    Medical condition: Vulvodynia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047781 Vulvodynia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA